PT-141 has a real approved dose to anchor to. As Vyleesi, bremelanotide is dosed at 1.75 mg subcutaneously on an as-needed basis, taken at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month.[1][2]
Reviewed for accuracy · Last reviewed July 7, 2026That regimen comes from the pivotal RECONNECT Phase 3 trials and the product label, both in premenopausal women with HSDD. Independently sourced PT-141 used off-label follows the same 1.75 mg figure by convention, but it carries none of the purity or accuracy testing of the approved autoinjector, and the approval does not extend to men or postmenopausal women.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.